IQVIA teams up with AstraZeneca to support COVID-19 vaccine development
16 July 2020 | News
This joint initiative is part of the U.S. government’s recently announced Operation Warp Speed project
Image credit- shutterstock.com
Leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry IQVIA has announced its collaboration with AstraZeneca to accelerate development of a potential new vaccine for COVID-19.
This joint initiative is part of the U.S. government’s recently announced Operation Warp Speed project.
Operation Warp Speed is part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.
The specific IQVIA and AstraZeneca collaboration will drive faster delivery of clinical studies in the U.S. aimed at demonstrating efficacy of AstraZeneca’s potential COVID-19 vaccine, AZD1222.
This initiative includes an expansive subject study, which is expected to begin enrolling participants this summer and will leverage IQVIA’s Virtual Trial solutions including Study Hub.
